ETO AntibodyProduct information
|100 µl (10 western blots)||-||Unavailable in your region|
Product Pathways - Lymphocyte Signaling
ETO Antibody #4498
|4498S||100 µl (10 western blots)||---||In Stock||---|
|4498||carrier free and custom formulation / quantity||email request|
|W||1:1000||Human, Mouse, Rat, Monkey||Endogenous||60||Rabbit|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting
Specificity / Sensitivity
ETO Antibody detects endogenous levels of ETO protein.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to amino acid sequence surrounding Ser270 of human ETO. Antibodies are purified by protein A and peptide affinity chromatography.
ETO belongs to a family of evolutionarily conserved nuclear factors. Although it has no DNA binding domains it is reported to act as a transcriptional corepressor (1). It is best characterized as the fusion partner of AML1 in acute myeloid leukemia with the t(8;21) translocation which gives rise to the AML-ETO fusion protein (2). AML1 is a transcription factor that is involved in the differentiation of all hematopoietic lineages. The fusion protein lacks the activation domain of AML1 and behaves as a dominant negative AML1, repressing AML1 target genes. AML-ETO also causes activation of other genes through a mechanism that involves Bcl-2 and enhanced expression of p21 waf1/cip1 (3,4). The AML-ETO fusion protein is thought to cause the expansion of a hematopoietic stem cell population that has limited lineage commitment and genomic instability (5). Recent evidence derived from chromatin immunoprecipitation (ChIP) experiments has demonstrated that ETO may play a role in the regulation of Notch target genes, and AML-ETO has been shown to disrupt repression of Notch target genes (6). Therefore, both AML and Notch target genes are deregulated by AML-ETO. Epigenetic silencing of the microRNA-223 gene has also been attributed to activities of AML-ETO, contributing to the differentiation block in t(8;21) leukemia (7).
- Davis, J.N. et al. (2003) Gene 303, 1-10.
- Downing, J.R. et al. (1993) Blood 81, 2860-5.
- Klampfer, L. et al. (1996) Proc Natl Acad Sci USA 93, 14059-64.
- Peterson, L.F. et al. (2007) Blood 109, 4392-8.
- Elagib, K.E. and Goldfarb, A.N. (2007) Cancer Lett 251, 179-86.
- Salat, D. et al. (2008) Mol Cell Biol 28, 3502-12.
- Nervi, C. et al. Epigenetics 3, 1-4.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.